Q3 2018 Sellas Life Sciences Group Inc Earnings Call

15/11/2018 8:00

Conference Call Sellas Life Sciences Group Inc

Sellas Life Sciences Group Inc Conference call will be held on Nov 15, 2018. During the earnings conference call's session Sellas Life Sciences Group Inc will provide updated information and financial status.
Conference call service enable to conduct an online meeting with several participates at the same time without leaving the room. Earnings call use teleconference platform to conduct an online meeting between the management of a public company, analysts, investors and the media to discuss the financial results during a given reporting period
In order to join the earnings online meeting, contact Sellas Life Sciences Group Inc for the information on connecting using web conferencing or bridge number and PIN code
Schedule an online meeting with QCONF conference service and get free conference bridge.
Galena Biopharma, Inc. ("we," "us," "our," "Galena" or the "Company") is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena's development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company's pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax(TM) (nelipepimut-S), GALE-301 and GALE-302. NeuVax is currently in a pivotal, Phase 3 breast cancer clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b clinical trial given sequentially with GALE-302.    
Read more Conference Call

Sellas Life Sciences Group Inc (GALE)

2000 Crow Canyon Place, San Ramon California 94583, United States